Picture of Bruker logo

BRKR — Bruker News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Medical equipment maker Bruker misses Q2 estimates, cuts forecast on academic market pressure

Overview

Bruker Q2 2025 revenue falls 0.4% yoy, missing analyst expectations

Non-GAAP diluted EPS drops 38.5% yoy, missing estimates, per LSEG data

Co announces cost savings initiative to reduce annual costs by $100-120 mln in FY 2026

Outlook

Bruker expects FY 2025 revenue of $3.43 to $3.50 bln

Company anticipates FY 2025 non-GAAP EPS of $1.95 to $2.05

Bruker sees organic revenue decline of 2% to 4% in FY 2025

Company cites US academic market pressure affecting FY 2025 outlook

Result Drivers

DEMAND PRESSURE - Life-science research instruments demand under pressure, particularly in US academic and biopharma markets, per CEO Frank H. Laukien

CURRENCY HEADWINDS - Tariffs and currency headwinds impacted results, despite mitigating actions

Key Details

MetricBeat/MissActualConsensus Estimate
Q2 RevenueMiss$797.40 mln$811.40 mln (11 Analysts)
Q2 Adjusted EPSMiss$0.32$0.42 (12 Analysts)
Q2 Net Income$4.20 mln
Q2 Gross Profit$357.90 mln
Q2 Operating Expenses$346 mln
Q2 Operating Income$11.90 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell" The average consensus recommendation for the advanced medical equipment & technology peer group is "buy" Wall Street's median 12-month price target for Bruker Corp is $47.50, about 20% above its August 1 closing price of $37.99 The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago Press Release: ID:nBw2PWc6Ba (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Bruker

See all news